Cite
APA Citation
Gupta, N., Wang, X., Offman, E., Rich, B., Kerstein, D., Hanley, M., Diderichsen, P. M., Zhang, P., & Venkatakrishnan, K. (2020). brigatinib Dose Rationale in Anaplastic Lymphoma Kinase–Positive Non‐Small Cell Lung Cancer: Exposure–Response Analyses of Pivotal ALTA Study. CPT: pharmacometrics & systems pharmacology, 9, 718–730. http://access.bl.uk/ark:/81055/vdc_100118051903.0x00000b